Prostatectomy did not notably reduce mortality in study

Share this article:

Radical prostatectomy did not significantly reduce all-cause mortality or prostate cancer mortality compared with observation through several years of follow-up among men with localized prostate cancer often detected by prostate-specific antigen (PSA) testing, a new study indicates.

A total of 731 men (mean age, 67 years) with localized prostate cancer (median PSA value, 7.8 ng per milliliter) were randomized to radical prostatectomy or to observation from November 1994 through January 2002, and were followed through January 2010. During the median follow-up of 10 years, 171 of 364 men (47%) assigned to radical prostatectomy died, compared with 183 of 367 men (49.9%) in the observation group. Adverse events within 30 days after surgery, including one death, occurred in 21.4% of patients.

In the radical prostatectomy group, 21 men (5.8%) died from prostate cancer or treatment, compared with 31 men (8.4%) assigned to observation. The effect of treatment on all-cause and prostate cancer mortality did not differ according to age, race, coexisting conditions, self-reported performance status, or histologic features of the tumor, but radical prostatectomy was associated with reduced all-cause mortality among men with a PSA value greater than 10 ng per milliliter, and possibly among men with intermediate-risk or high-risk tumors (N Engl J Med. 2012;367:203-213).

Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

April Contest: Win a Pebble Watch

Start the contest today

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Web Exclusives

Genes may predict the need for further cancer treatments

A new predictive tool is being developed that could help patients with breast cancer and certain lung cancers decide whether follow-up treatments are likely to help.

Early promise from therapy targeting FGFR mutations

The investigational drug BGJ398 showed promising anticancer activity in patients with various types of cancer driven by FGFR genetic alterations.

New immunotherapy promising for advanced melanoma

A new type of immunotherapy that directs patients' immune responses toward tumor cell killing, IMCgp100, showed efficacy in some patients with advanced melanoma.